We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect PTC Therapeutics (PTCT - Free Report) to post quarterly loss of $1.54 per share in its upcoming report, which indicates a year-over-year increase of 12.5%. Revenues are expected to be $173.51 million, down 11.7% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 2.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some PTC Therapeutics metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Revenues- Net product revenue' should arrive at $111.28 million. The estimate suggests a change of -22.7% year over year.
Analysts expect 'Revenues- Royalty revenue' to come in at $62.95 million. The estimate indicates a change of +25.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Net product revenue- Emflaza' reaching $36.89 million. The estimate indicates a year-over-year change of -44.9%.
Analysts forecast 'Revenues- Net product revenue- Translarna' to reach $65.30 million. The estimate indicates a year-over-year change of -5.4%.
Over the past month, PTC Therapeutics shares have recorded returns of +0.3% versus the Zacks S&P 500 composite's +0.7% change. Based on its Zacks Rank #3 (Hold), PTCT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect PTC Therapeutics (PTCT - Free Report) to post quarterly loss of $1.54 per share in its upcoming report, which indicates a year-over-year increase of 12.5%. Revenues are expected to be $173.51 million, down 11.7% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 2.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some PTC Therapeutics metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Revenues- Net product revenue' should arrive at $111.28 million. The estimate suggests a change of -22.7% year over year.
Analysts expect 'Revenues- Royalty revenue' to come in at $62.95 million. The estimate indicates a change of +25.5% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Net product revenue- Emflaza' reaching $36.89 million. The estimate indicates a year-over-year change of -44.9%.
Analysts forecast 'Revenues- Net product revenue- Translarna' to reach $65.30 million. The estimate indicates a year-over-year change of -5.4%.
View all Key Company Metrics for PTC Therapeutics here>>>
Over the past month, PTC Therapeutics shares have recorded returns of +0.3% versus the Zacks S&P 500 composite's +0.7% change. Based on its Zacks Rank #3 (Hold), PTCT will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>